In TCGA dataset, the SGO2 mRNA expression level was significantly higher in the WHO grade IV (n = 152) than in grade III gliomas (n = 130; p = 3.91 × 10–18) and in grade II gliomas (n = 61; p = 1.14 × 10−40). This evidence concerns the gene SGO2 and central nervous system cancer.